Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Homology Medicines Inc.

Headquarters: Bedford, MA, United States of America
Website: N/A
Year Founded: 2015
Status: Reverse-merged

BioCentury | Feb 25, 2025
Emerging Company Profile

Lifordi: Applying ADCs to autoimmune conditions

With $70M series A, biotech backed by Arch, 5am and Atlas is developing a targeted steroid it believes will be safer, with lower and less frequent dosing
BioCentury | Apr 18, 2024
Product Development

Rare disease spotlight: a leukodystrophy with small pipeline behind first approval

At least three MLD programs are coming up behind Orchard’s Lenmeldy, although three others were recently discontinued
BioCentury | Jan 17, 2024
Management Tracks

CEO departures at Aclaris and Vaxart

Plus: David Pyrce named CEO at Cognigenics, and updates from NextPoint, Hookipa, NeoImmuneTech, Neurogene, Paratek and Aspen
BioCentury | Dec 20, 2023
Data Byte

2023’s biotech reverse mergers

Half of the U.S.-listed biotechs that announced reverse mergers this year had been public for four years or less
BioCentury | Nov 16, 2023
Deals

Nov. 16 Quick Takes: Q32 takes merger route to NASDAQ via Homology deal

Plus: SpringWorks’ neurofibromatosis program headed for NDA and updates from Astellas, Propella, BMS, Merck, Nature’s Toolbox, Apollomics and Avistone
BioCentury | Jul 29, 2023
Deals

July 28 Quick Takes: AZ’s Alexion picks up Pfizer gene therapies

Plus: Homology exploring options and updates from Siga, BrainStorm
BioCentury | Mar 10, 2023
Management Tracks

Drachman leaving Neoleukin amid restructuring

Plus: Aspesi to lead HR at Editas and updates from Homology, GlycoMimetics and Ajax
BioCentury | Nov 23, 2022
Data Byte

Phenylketonuria pipeline breaks into new modalities

New approaches go beyond small molecules and enzymes to bacteria, mRNA, protein and gene therapies
BioCentury | Sep 27, 2022
Management Tracks

DEM names Grmusa CEO, Quéva CSO

Plus 5AM adds Arthur Tzianabos, June Lee as venture partners, and updates from Woebot, Flagship Biosciences and Radionetics
BioCentury | Sep 7, 2022
Management Tracks

Harpoon’s McMahon becomes CEO at Storm

Plus new CFO, CSO at Voyager and updates from Sonoma, Garuda, Alloy, Homology and more
Items per page:
1 - 10 of 58
Help Center
Username
Request a Demo
Request Training
Ask a Question